1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsElucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed) Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed) Agency: National Institutes of Health Assistance Listings: 93. 855 -- Allergy and Infectious Diseases Research Last Updated: May 13, 2026 View version history on Grants.
gov The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or Hepatitis B Virus (HBV).
This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, Tuberculosis (TB) and HBV disease progression.
Independent school districts Private institutions of higher education Public and state institutions of higher education For-profit organizations other than small businesses Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Public and Indian housing authorities Federally recognized Native American tribal governments Special district governments City or township governments Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. File name Description Last updated PAR-25-316-Full-Announcement.
html PAR-25-316 Full Announcement Text Dec 18, 2024 08:07 PM UTC Link to additional information https://grants. nih. gov/grants/guide/pa-files/PAR-25-316.
html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Open to various organization types, including nonprofit organizations. Confirm the full requirements in the official notice before applying.
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article